Treatment of Patients With Gastric Cancer by Surgery, Radiotherapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study
The 5-year survival rate of gastric cancer is between 8% and 9% and has not improved over the past 3 decades. In the American literature [1–3, 5, 6, 8, 9, 11], it is reported that the application of adjuvant chemotherapy after gastric resection has led to an improvement in the survival rate. Some studies in locally unresectable gastric cancer record an improved survival when 5-fluorouracil (5-FU) is combined with local radiotherapy [1, 10]. Reitemeier et al.  and Heidelberger et al.  pointed out that certain transplanted tumors showed a regression as well as prolonged survival when treated by irradiation therapy in addition to 5-FU. Working on this basis, Moertel et al. studied the effect of combined 5-FU and supervoltage radiotherapy and found that they gave significant objective asymptomatic palliation in some patients having gastrointestinal cancer . It is thought that 5-FU acts as a radiosensitizor or at least as a synergistic adjuvant when given simultaneously with radiotherapy to the primary tumor. Moreover, 5-FU is given systematically and thus exerts its desirable effects on the floating cells in the circulation as well as on metastatic foci in distant organs.
KeywordsToxicity Adenocarcinoma Diarrhea Pyrimidine Leukopenia
Unable to display preview. Download preview PDF.
- 1.Childs, D. S., Moertel, C. G., Holbrook, M. A., Reitemeier, R. J., Colby, M.: Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation. Am. J. Roentgenol. 102, 541–544 (1968).Google Scholar
- 7.Moertel, C. G., Reitemeier, R. J.: Advanced gastrointestinal cancer. In: Clinical management and chemotherapy, p. 164. New York: Harper & Row 1969.Google Scholar